Philip A.  Pizzo net worth and biography

Philip Pizzo Biography and Net Worth

Dr. Pizzo has served as a member of GBT’s board of directors since September 2015. He is a leader in academic medicine, championing programs and policies to improve the future of science, education and healthcare in the United States and beyond. He currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. He also serves on the board of directors of MRI Interventions, Inc., a medical device company. He previously served as dean of the Stanford School of Medicine, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs. He serves on several international boards. Dr. Pizzo received a B.A. from Fordham University and an M.D. from the University of Rochester School of Medicine.

What is Philip A. Pizzo's net worth?

The estimated net worth of Philip A. Pizzo is at least $624,080.88 as of June 21st, 2022. Dr. Pizzo owns 9,112 shares of Global Blood Therapeutics stock worth more than $624,081 as of November 13th. This net worth evaluation does not reflect any other assets that Dr. Pizzo may own. Learn More about Philip A. Pizzo's net worth.

How do I contact Philip A. Pizzo?

The corporate mailing address for Dr. Pizzo and other Global Blood Therapeutics executives is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Global Blood Therapeutics can also be reached via phone at (650) 741-7700 and via email at [email protected]. Learn More on Philip A. Pizzo's contact information.

Has Philip A. Pizzo been buying or selling shares of Global Blood Therapeutics?

Philip A. Pizzo has not been actively trading shares of Global Blood Therapeutics over the course of the past ninety days. Most recently, Philip A. Pizzo sold 1,260 shares of the business's stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a transaction totalling $34,335.00. Following the completion of the sale, the director now directly owns 9,112 shares of the company's stock, valued at $248,302. Learn More on Philip A. Pizzo's trading history.

Who are Global Blood Therapeutics' active insiders?

Global Blood Therapeutics' insider roster includes Eric Fink (Insider), Scott Morrison (Director), and Philip Pizzo (Director). Learn More on Global Blood Therapeutics' active insiders.

Philip A. Pizzo Insider Trading History at Global Blood Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2022Sell1,260$27.25$34,335.009,112View SEC Filing Icon  
6/18/2021Sell1,065$36.54$38,915.107,837View SEC Filing Icon  
12/11/2019Sell30,000$76.57$2,297,100.0015,000View SEC Filing Icon  
See Full Table

Philip A. Pizzo Buying and Selling Activity at Global Blood Therapeutics

This chart shows Philip A Pizzo's buying and selling at Global Blood Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Global Blood Therapeutics Company Overview

Global Blood Therapeutics logo
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $68.49
Low: $68.49
High: $68.49

50 Day Range

MA: $68.47
Low: $68.07
High: $68.49

2 Week Range

Now: $68.49
Low: $21.65
High: $73.02

Volume

74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45